4,614 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
Avoid IBM Until It Can Regain Its Innovation Capability https://seekingalpha.com/article/4248611-avoid-ibm-can-regain-innovation-capability?source=feed_all_articles Mar 13, 2019 - International Business Machines' total return underperformed the DOW average for my 51 month test period by 43.10%, which is poor, you may as well leave the money in the bank.International Business Ma
HTG Molecular Diagnostics, Inc. (HTGM) CEO TJ Johnson on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4248283-htg-molecular-diagnostics-inc-htgm-ceo-tj-johnson-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Mar 12, 2019 - HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Q4 2018 Results Earnings Conference Call March 07, 2019 04:30 PM ET Company Participants Monique Kosse - Investor Relations TJ Johnson - Chief Executive O
Senate panel asks CVS and four other pharmacy middlemen to testify about drug prices https://www.cnbc.com/2019/03/12/senate-panel-asks-cvs-and-other-middlemen-to-testify-about-drug-prices.html Mar 12, 2019 - Senate Finance Committee Chairman Chuck Grassley, R-Iowa., and Ron Wyden, D-Ore., the committee's ranking member, asked Cigna, CVS, Humana, OptumRx and Prime Therapeutics to testify on Capitol Hill on April 3.
Orthofix Shares Waylaid by Margin Squeeze, Disappointing Outlook for 2019 http://www.gurufocus.com/news/831486/orthofix-shares-waylaid-by-margin-squeeze-disappointing-outlook-for-2019 Mar 12, 2019 - Orthofix Shares Waylaid by Margin Squeeze, Disappointing Outlook for 2019, Stocks: OFIX,SYK,MDT,JNJ,ZBH, release date:Mar 12, 2019
Johnson & Johnson files U.S. marketing application for expanded use of Darzalex https://seekingalpha.com/news/3442078-johnson-and-johnson-files-u-s-marketing-application-expanded-use-darzalex?source=feed_news_all Mar 12, 2019 - Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical has submitted a supplemental marketing application to the FDA seeking approval for Darzalex (daratumumab), combined with Celgene's (NASDAQ:
Sage And Axsome Face Off In Depression https://seekingalpha.com/article/4248099-sage-axsome-face-depression?source=feed_sector_healthcare Mar 12, 2019 - AXSM recently announced results from a trial of AXS-05 in major depressive disorder.SAGE announced results from a trial of SAGE-217 in major depressive disorder in late 2017.AXS-05 and SAGE-217 could
My Dividend Growth Portfolio Off To A Good Start In 2019 https://seekingalpha.com/article/4247900-dividend-growth-portfolio-good-start-2019?source=feed_all_articles Mar 11, 2019 - My portfolio fully recovered from December's decline in value.Dividends are higher so far this year.I provide an update for the first two months of 2019.
AT&T Is A Buy For The Very Conservative Income Investor With Time Warner Growth Potential A Plus https://seekingalpha.com/article/4247787-t-buy-conservative-income-investor-time-warner-growth-potential-plus?source=feed_all_articles Mar 11, 2019 - AT&T has increased its dividend for 34 years (a dividend Aristocrat) with a well above average present 6.8% yield.AT&T's total return underperformed the Dow average for my 51 month test period by 32.9
Bayer Submits Application in EU for Prostate Cancer Drug http://www.zacks.com/stock/news/358754/bayer-submits-application-in-eu-for-prostate-cancer-drug?cid=CS-ZC-FT-358754 Mar 11, 2019 - Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Simulations Plus: Has Fantastic Total Return And Growth In The Drug Simulation Testing Market https://seekingalpha.com/article/4247742-simulations-plus-fantastic-total-return-growth-drug-simulation-testing-market?source=feed_all_articles Mar 11, 2019 - Simulations Plus total return overperformed the Dow average for my 51-month test period by 217.10% which is fantastic.Simulations Plus three-year past CAGR of 24% is well above average and will give y

Pages: 12345678...462

<<<Page 3>